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ABSTRACT 
Objective: Drugs that have narrow absorption window in the gastrointestinal tract (GIT) will have poor absorption. For these drugs, gastro retentive drug delivery systems offer 
the advantage in prolonging the gastric emptying time. Atenolol is an antihypertensive drug, which has low elimination half life: 3–4 hrs. The floating tablets of Atenolol were 
prepared to increase the gastric retention and to improve the bioavailability of the drug. Atenolol was chosen as a model drug because it is better absorbed in the stomach 
than the lower gastro intestinal tract.   
Methods: The floating tablets were formulated using HPMC K4M and HPMC K100M as the release retardant polymers, and sodium bicarbonate as the gas generating agent 
to reduce the floating lag time. The tablets were prepared by direct compression.  
Results: The formulated tablets were evaluated for weight variation, hardness, friability, swelling index floating lag time, total floating time and dissolution rate in pH 1.2. The 
floating tablets extended the drug release up to 8 hrs. The drug-polymer interaction was evaluated by fourier transform infrared spectroscopy (FTIR). The FTIR study indicated 
the lack of drug-polymer interaction. 
Conclusion: Eight Formulations of Floating tablets of Atenolol were developed by direct compression technique. The F8 Formulation was found to be best of all the trails 
showing that the drug release matches with brand product. 
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INTRODUCTION 
Oral Controlled Release Drug Delivery Systems
 
Oral controlled release drug delivery is a drug delivery system that 
provides the continuous oral delivery of drugs at predictable and 
reproducible  kinetics  for  a  predetermined  period  throughout  the 
course of GI transit and also the system that target the delivery of 
a drug to a specific region within the GI tract for either local or 
systemic action [1,2].  
All the pharmaceutical products formulated for systemic delivery 
via the oral route of administration, irrespective of the mode of 
delivery  (immediate,  sustained  or  controlled  release)  and  the 
design  of  dosage  form  (solid  dispersion  or  liquid),  must  be 
developed  within  the  intrinsic  characteristics  of  GI  physiology. 
Therefore  the  scientific  framework  required  for  the  successful 
development  of  oral  drug  delivery  systems  consists  of  basic 
understanding of  
(i)  Physicochemical,  pharmacokinetic  and  pharmacodynamic 
characteristics of the drug 
(ii)   The  anatomic  and  physiologic  characteristics  of  the 
gastrointestinal tract and  
(iii)  Physicochemical characteristics and the drug delivery mode 
of the dosage form to be designed.  
The main areas of potential challenge in the development of oral 
controlled drug delivery systems are [3,4]
  
  Development of a drug delivery system: To develop a viable 
oral  controlled  release  drug  delivery  system  capable  of 
delivering  a  drug  at  a  therapeutically  effective  rate  to  a 
desirable site for duration required for optimal treatment.  
  Modulation of gastrointestinal transit time: To modulate the 
GI transit time so that the drug delivery system developed 
can be transported to a target site or to the vicinity of an 
absorption  site  and  reside there  for  a  prolonged  period  of 
time to maximize the delivery of a drug dose.  
  Minimization of hepatic first pass elimination: If the drug to be 
delivered  is  subjected  to  extensive  hepatic  first-pass 
elimination, preventive measures should be devised to either 
bypass or minimize the extent of hepatic metabolic effect.  
Gastro retentive Dosage Form (GRDF)
 [5,6] 
It is evident from the recent scientific and patient literature that an 
increased  interest  in  novel  dosage  forms  that  are  retained  in 
stomach  for  a  prolonged  and  predictable  period  of  time  exists 
today  in  academic  and  industrial  research  groups.  One  of  the 
most  feasible  approaches  for  achieving  a  prolonged  and 
predictable drug delivery in the GI tract is to control the gastric 
residence time (GRT), i.e. gastro retentive dosage form (GRDFs 
or GRDS).  
GRDFs  extend  significantly  the  period  of  time  over  which  the 
drugs may be released. They not only prolong dosing intervals, 
but also increase patient compliance beyond the level of existing 
controlled release dosage form.  
Dosage  form  with  prolonged  GRT,  i.e.  gastro  retentive  dosage 
form  (GRDF),  will  bring  about  new  and  important  therapeutic 
options such as –  
  This  application  is  especially  effective  in  sparingly  soluble 
and insoluble drugs, as the solubility of a drug decreases, 
the  time  available  for  drug  dissolution  becomes  less 
adequate and thus the transit time becomes affecting drug 
absorption.  To  override  this  problem,  erodible,  gastro 
retentive  dosage  forms  have  been  developed  that  provide 
continuous,  controlled  administration  of  sparingly  soluble 
drugs at the absorption site.  
  GRDFs greatly improve the pharmacotherapy of the stomach 
through  local  drug  release,  leading  to  high  drug 
concentration  at  the  gastric  mucosa.  (For  e.g.  Eradicating 
Helicobacter pylori from the sub mucosal tissue of Stomach).  
  GRDFs  can  be  used  as  carriers  for  drugs  with  so-called 
absorption  windows.  These  substances  for  e.g.  antiviral, 
antifungal and antibiotic agents are taken up only from very 
specific sites of the GI mucosa. 
Materials Used 
Atenolol,    HPMC  K  15M,  HPMC  K  100M,  Sodium  Carbonate, 
Micro  Crystalline  Cellulose,  Magnesium  Sterate  and  Talc  were 
procured from SD Fine Chemicals, Mumbai. All other chemicals 
used were of analytical grade. Brahmaiah et al                                                                                                       Mintage journal of Pharmaceutical & Medical Sciences│24-28 
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METHODS USED 
Preparation of Atenolol floating tablets 
All the formulations were prepared by direct compression method 
using  different  viscosity  grades  of  HPMC  polymers  in  various 
ratios (designated as F-1 to F-8 in Table). The Atenolol and all 
other ingredients were individually passed through sieve ≠ 60. All 
the ingredients were mixed thoroughly by triturating up to 15 min. 
The powder mixture  was lubricated with talc. The single punch 
tablet machine (CADMACH) was used for the compression of the 
floating  tablets.  Use  of  ingredients  in  the  formulation:  Sodium 
bicarbonate was used as the gas generating agent to reduce the 
floating lag time. HPMC K4M and HPMC K100M were used as the 
release retardant polymer to obtain prolonged release of the drug 
up to 8 hours. Microcrystalline cellulose (MCC) was used as the 
diluent. Magnesium stearate and talc were used as the lubricants. 
The  tablets  were  prepared  by  using  the  direct  compression 
method. 
EVALUATION OF TABLETS [7, 8, 9, 10] 
The  formulated  tablets  were  evaluated  for  the  following 
physicochemical characteristics: 
General appearance 
The formulated tablets were assessed for its general appearance 
and observations were made for shape, color, texture and odor.   
 Hardness  
Hardness  of  the tablet  was  determined  by  using the  Monsanto 
hardness tester. The lower plunger was placed in contact with the 
tablet and a zero reading was taken. The plunger was then forced 
against  a  spring  by  turning  a  threaded  bolt  until  the  tablet 
fractured. As the spring was compressed a pointer rides along a 
gauge in the barrel to indicate the force.  
Weight Variation 
20 tablets were selected and weighed collectively and individually. 
From the collective weight, average weight was calculated. Each 
tablet weight was then compared with average weight to ascertain 
whether it was within the permissible limits or not. Not more than 
two of the individual weights deviated from the average weight by 
more than 7.5% for 300 mg tablets and none by more than double 
that percentage.  
Friability test 
20  previously  weighed  tablets  were  placed  in  the  friability 
apparatus, which was given 100 revolutions and the tablets were 
reweighed. The percentage friability was calculated by using the 
following formula,  
Percentage friability = initial weight-final weight /initial weight × 
100. 
Drug content 
20 tablets of each formulation were weighed and powdered. The 
quantity  of  powder  equivalent  to  100  mg  of  Atenolol  was 
transferred  in  to  a  100  ml  volumetric  flask  and  the  volume 
adjusted  to  100ml  with  0.1N  HCl.  Further  1ml  of  the  above 
solution was diluted to 100 ml with 0.1N HCl and the absorbance 
of the resulting solution was observed at 221 nm.  
In vitro Buoyancy studies 
The in vitro buoyancy was determined by floating lag time, and 
total floating time. (As per the method described by Rosa et al 
8) 
The tablets were placed in a 100ml beaker containing 0.1N HCl. 
The time required for the tablet to rise to the surface and float was 
determined as floating lag time (FLT) and the duration of the time 
the tablet constantly floats on the dissolution medium was noted 
as the Total Floating Time respectively (TFT). 
Swelling index studies 
 The  swelling  behavior  of  a  dosage  unit  was  measured  by 
studying  its  weight  gain.  The  swelling  index  of  tablets  was 
determined  by  placing  the  tablets  in  the  basket  of  dissolution 
apparatus  using  dissolution  medium  as  0.1N  HCl  at  37±0.5°C. 
After 0.5, 1, 2, 3, 4, 5, and 6h, each dissolution basket containing 
tablet  was  withdrawn,  blotted  with  tissue  paper  to  remove  the 
excess water and weighed on the analytical balance (Schimdzu, 
AX 120). The experiment was performed in triplicate for each time 
point.  Swelling  index  was  calculated  by  using  the  following 
formulae 
Swelling index = (Wet weight of tablet – Dry weight of tablet) 
                Dry weight of tablet. 
Dissolution Study [11] 
900ml 0f 0.1 HCl was placed in the vessel and the USP apparatus 
–II (Paddle Method) was assembled. The medium was allowed to 
equilibrate to temp of 37 + 0.5°C. Tablet was placed in the vessel 
and the vessel was covered, the apparatus was operated for 8 
hours at 50 rpm. At definite time intervals, 5ml of the fluid was 
withdrawn;  filtered  and  again  5ml  of  the  fluid  was  replaced.  
Suitable  dilutions  were  done  with  the  dissolution  fluid  and  the 
samples were analyzed spectrophotometrically at 221 nm.  
Release Kinetics [12] 
The analysis of drug release mechanism from a pharmaceutical 
dosage  form  is  an  important  but  complicated  process  and  is 
practically  evident  in  the  case  of  matrix  systems.  As  a  model-
dependent  approach,  the  dissolution  data  was  fitted  to  four 
popular release models such as zero-order, first-order, diffusion 
and Peppa’s- Korsemeyer equations, which have been described 
in the literature. The order of drug release from matrix systems 
was described by using zero order kinetics or first orders kinetics.  
FT-IR STUDIES 
The FTIR spectra of the drug (alone), polymer (alone) and the 
drug-polymer (mixture) were recorded by the potassium bromide 
pellet method. From the infrared spectra it is clearly evident that 
there were no drug-polymer interactions of the drug.  
DATA FOR IR SPECTRA OF ATENOLOL 
Functional Group  Frequency  (cm
-1) 
C-H Aromatic (stretching)  3017.49 
c=c  Aromatic (stretching)  1404.72 
C-N   (stretching)  1179.15 
C-H   (stretching)  2870.16 
CH2  (bending)  1421.05 
O-H   (stretching)  3342.05 
 
Table1: Composition of different formulations 
Formulation 
No. 
Atenolol (mg)  HPMC  
K15M(mg) 
HPMC  
K100M(mg) 
NaHCO3  
(mg) 
Mag. 
Stearate(mg) 
Talc(mg)  Microcrystalline  
Cellulose (mg) 
F1  50  50  -----  45  3  3  154 
F2  50  100  -----  45  3  3  99 
F3  50  150  -----  45  3  3  49 
F4  50  200  -----  45  2.5  2.5  ----- 
F5  50  -----  50  45  3  3  154 
F6  50  -----  100  45  3  3  99 
F7  50  -----  150  45  3  3  49 
F8  50  -----  200  45  2.5  2.5  ----- Brahmaiah et al                                                                                                       Mintage journal of Pharmaceutical & Medical Sciences│24-28 
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studied  by  using  Higuchi  equation  and  Peppa’s-  Korsemeyer 
equation. The results are given in Table. 
Higuchi equation 
It defines a linear dependence of the active fraction released per 
unit of surface (Q) on the square root of time. 
Q=K2t
½ 
 
Where, K2 is the release rate constant. 
Power Law 
In order to define a model, which would represent a better fit for 
the formulation, dissolution data was further analyzed by Peppa’s 
and Korsemeyer equation (Power Law). 
Mt/M = K.t
n 
RESULTS 
Table 2: Quality Control Parameters of Atenolol floating Table
Formulation 
No. 
Avg. Weight 
(Mean± S.D) 
(n=20) 
Hardness 
(kg/cm
2) 
(n=3) 
Friability 
(Mean±S.D) 
(n=20) 
% Drug content 
(mg) 
Buoyancy 
Lag time 
(min) 
Total floating 
Time(hrs) 
Matrix 
integrity 
F1  283±0.6  7.2±0.2  0.546  97±0.7  4  8  + 
F2  320±0.9  7.5±0.2  0.612  99±0.5  10  8  + 
F3  297±0.3  8.0  0.827  100±0.6  8  8  + 
F4  291±0.4  7.6±0.2  0.611  99±0.6  6.1  8  + 
F5  286±0.8  7.6±0.2  0.625  99±0.6  5.0  8  + 
F6  304±0.8  7.3±0.4  0.655  98±0.5  3  8  + 
F7  294±0.4  8  0.711  100±0.3  8.5  8  + 
F8  292±0.4  7.7±0.5  0.702  99±0.4  8.6  8  + 
Table3: Swelling index studies of Atenolol floating tablets 
prepared with HPMC K15 M in different ratios 
 
Time(hr) 
Swelling index ratio (n=3) 
F1  F2  F3  F4 
0  0  0  0  0 
1  44.64  48.43  51.23  60 
2  80.35  101.56  115.6  120 
3  98.21  143.75  158.36  169.09 
4  103.57  158.62  175.63  223.63 
5  110.7  169.5  195  234.54 
6  110.7  175.56  200.85  249.09 
Table 4: Swelling index studies of Atenolol floating tablets 
prepared with HPMC K100 M in different ratios 
 
Time(hr) 
Swelling index ratio (n=3) 
F5  F6  F7  F8 
0  0  0  0  0 
1  81.03  85.48  92.87  107.14 
2  96.55  124.19  132.53  157.14 
3  108.62  164.5  180.69  207.14 
4  110.34  179.03  190.56  228.57 
5  143.1  248.38  269.87  307.14 
6  162.06  275.8  290.96  325 
Table 5: Highest swelling index profile of Atenolol floating 
tablets different formulations 
sr.no.  Formulation code  Highest swelling index ratio 
1  F1  44.64 
2  F2  48.43 
3  F3  51.23 
4  F4  60 
5  F5  81.03 
6  F6  85.48 
7  F7  92.87 
8  F8  107.14 
 
 
Fig. 1: Swelling index of the different formulations (F1-F4) 
 
 
Fig. 2: Swelling index of the different formulations (F5-F8) 
 
Fig. 3: Highest swelling index of the floating tablets 
Table 6: Dissolution Data of Atenolol Tablets   Prepared with 
hpmc K15M IN Different concentrations 
Time 
(hr) 
Cumulative percent drug dissolved (n=3+sd) 
F1  F2 
0.5  18.45±0.77  17.76±0.77 
1  27.05±0.55  25.02±0.5 
2  34±0.69  31.68±0.84 
3  42.58±0.99  40.35±0.96 
4  49.86±0.77  47.3±0.55 
5  55.4±0.95  53.69±0.52 
6  65.17±1.25  63.25±0.95 
7  70.01±0.95  69.64±1.25 
8  76.8±1.08  75.41±0.99 
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Fig. 4: Dissolution profile of Atenolol floating tablets (F1, F2) 
formulations. 
Table 7: Dissolution Data Of Atenolol Tablets Prepared With 
Hpmc K 15m In Different Concentrations 
Time 
(hr) 
      cumulative percent drug 
dissolved (n=3+sd) 
  F3  F4 
0.5  16.85±0.65  14.97±0.98 
1  20.05±0.25  19.65±1.20 
2  31.97±0.62  29.14±1.58 
3  40.15±0.85  37.12±0.25 
4  46.69±0.78  41.63±0.52 
5  50.79±0.85  49.42±0.88 
6  61.27±0.95  59.23±0.80 
7  66.73±0.58  64±0.95 
8  71.34±1.05  70±1.0 
Table 8: Dissolution Data Of Atenolol Tablets Prepared With 
Hpmc K100m In Different Concentrations 
TIME 
(hr) 
CUMULATIVE percent drug dissolved (n=3+sd) 
f5  f6 
0.5  17.46±0.77  15.85±0.55 
1  24.9±0.52  20.08±0.66 
2  33.41±0.84  29.71 ±0.95 
3  40.62±0.66  38.49 ±0.58 
4  45.63±0.61  43.32 ±0.39 
5  51.26±0.59  49.85 ±0.89 
6  60.92±0.35  59.13±0.94 
7  66.08±0.92  64.45±0.88 
8  70.44±0.94  69.64±0.90 
 
 
 
Fig. 5: Dissolution profile of Atenolol floating tablets (F3, F4) 
 
Fig. 6: Dissolution profile of Atenolol floating tablets (F5, F6) 
 
Table 9: Dissolution Data of Atenolol Tablets Prepared with 
HPMC K100M IN Different concentrations 
Time 
(hr) 
      cumulative percent drug dissolved (n=3+sd) 
               f7                 f8  Brand 
0.5  12.81±0.88  10.04±0.58  9.29±0.52 
1  17.4±0.54  16.85±0.77  15.02±0.74 
2  25.25±0.65  23.42±0.69  21.17±0.45 
3  35.89±0.98  32.63±0.25  29.3±0.52 
4  41.51±0.58  35.92±0.89  32±0.84 
5  47.53±0.85  41.61±0.58  40.83±0.90 
6  49.59±0.69  47.28±0.98  47.23±0.48 
7  59.31±0.58  52.34±0.58  52.74±0.56 
8  62.24±0.85  61.31±0.65  59.67±0.48 
 
 
Fig. 7: dissolution profile of atenolol floating tablets (f7, f8 
and brand) formulations. 
Table 10: Release kinetics: Coefficient of correlation (r) 
values of   different batches of   Atenolol floating tablets 
Formulation  Zero 
order  
First 
order 
Higuchi’s  Peppa’s 
F1  0.976  0.870  0.929  0.934 
F2  0.975  0.915  0.954  0.971 
F3  0.937  0.940  0.996  0.994 
F4  0.971  0.990  0.994  0.995 
F5  0.983  0.923  0.957  0.966 
F6  0.992  0.954  0.966  0.975 
F7  0.975  0.955  0.970  0.985 
F8  0.979  0.981  0.986  0.994 
BRAND  0.995  0.987  0.977  0.992 
 
Table 11: Dissolution Parameters Of Atenolol Tablets 
 
Formulation  
                 Dissolution Parameters 
n  K0(µg/hr)  K1(hr-1)  T25(hr)  T50(hr)  T75(hr) 
F1  0.492  7.831  0.301  0.9  5  8 
F2  0.591  8.084  0.248  1  5.1  8 
F3  0.608  8.077  0.223  1.4  5  --- 
F4  0.612  5.503  0.204  1.5  5.6  --- 
F5  0.496  7.819  0.186  1  5  ---- 
F6  0.599  7.867  0.175  1.5  5  --- 
F7  0.621  6.626  0.151  2  6  --- 
F8  0.623  5.490  0.175  2.2  7  --- 
BRAND  0.655  6.762  0.179  2.5  7  --- 
DISCUSSION 
The objective of the present study was to prepare Floating tablets 
of  Atenolol.  These  were  developed  to  prolong  the  gastric 
residence time and to increase the drug bioavailability. Atenolol 
was chosen as a model drug because it is better absorbed in the 
stomach than the lower gastro intestinal tract. The tablets were 
prepared by direct compression technique, using polymers such 
as  HPMCK15M,  HPMC  K100M  and  other  standard  excipients. 
Tablets  were  evaluated  for  physical  characteristics  such  as 
hardness,  floating  capacity  and  weight  variation.  The  in  vitro 
release characteristics were evaluated for 8hrs. 
Totally    8  different  formulations  of  Atenolol  were  prepared  by 
using two different polymers like HPMC K15M, HPMC K100M and 
diluent  microcrystalline cellulose in different concentrations. The 
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the  concentration  of  the  polymer  used.    Finally,  the  retardant 
effect of the polymer on the drug release can be indicated as  
HPMC K100M > HPMC K15M. 
Swelling  is  crucial  in  determining  the  release  rate.  A  direct 
correlation between swelling and drug release was observed and 
the  swelling  indices  were  increased  with  increase  in  polymer 
concentration.  Among  all  the  formulations  the  F8  formulation 
containing HPMC K100M shows the best result of swelling index. 
Among all the formulations the F8 formulation containing HPMC 
K100M shows the best result. The result was compared with the 
branded formulation. The result was satisfactory .      
Tables enlist the various dissolution parameters computed for all 
the  controlled  release  floating  tablets.  To  examine  the  release 
mechanism of Atenolol floating tablets, the results were analyzed 
according to Korsemeyer- Peppas equation. 
Release of Atenolol from the optimized formulation (F8) was found 
to  follow  First  order  kinetics  (correlation  coefficient,  r
2  value 
0.981). 
Higuchi  plot  showed  an  r
2  valve  of  0.986  for  formulation  F8 
suggesting  that  the  diffusion  plays  an  important  role  in  the 
controlled release. The data was fitted to Korsemeyer equation; 
and the value of diffusion exponent ‘n’ (0.623) indicated that the 
drug release shows Non-fickian diffusion. 
CONCLUSION 
The  Atenolol  is  a  selective  β1-adrenoreceptor  blocking  agent 
which  is  used  in  the  treatment  of  hypertension.  In  this  study 
Atenolol  tablets  were  prepared  by  using  different  polymers  like 
HPMC K15M and K100M. 
Eight formulations of floating tablets of Atenolol were developed 
by direct compression technique. The F8 formulation was found to 
be best of all the trials showing that the drug release matches with 
the brand product. 
The  best  formulation  F8  can  successfully  be  employed  as  a 
controlled  release  floating  drug  delivery  system.  The  floating 
tablets  can  control  the  fluctuations  in  the  plasma  drug 
concentration, increase the gastric residence time and eventually 
improve  the  bioavailability  of  the  drug.    Based  upon  the  FTR 
studies we conclude that there is no drug-excepient interactions. 
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